NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $1.77 0.00 (0.00%) Closing price 04/7/2025 04:00 PM EasternExtended Trading$1.79 +0.02 (+1.07%) As of 04/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Akebia Therapeutics Stock (NASDAQ:AKBA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$1.63▼$1.8250-Day Range$1.69▼$2.8452-Week Range$0.80▼$2.89Volume4.21 million shsAverage Volume2.73 million shsMarket Capitalization$418.13 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingBuy Company OverviewAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 276th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -7.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -7.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Akebia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.92% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 11.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.35 Percentage of Shares Shorted7.92% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 11.36%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.50 News SentimentAkebia Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Akebia Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 30 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows6 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,216.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Stock News HeadlinesAkebia Therapeutics: CHMP Adopts Positive Opinion On XOANACYL - Quick FactsApril 5 at 7:43 PM | nasdaq.comAkebia announces CHMP positive opinion for XOANACYLApril 4, 2025 | markets.businessinsider.comGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively stockpiling gold at any price, the market is showing no signs of slowing down. In fact, gold has recently reached new all-time highs, driven by expectations of interest rate cuts and increasing safe-haven demand. This trend has led to a significant boost in gold mining stocks and gold-focused investment funds. But here's the exciting part: I've found a way to get exposure to MORE than an ounce of gold for under $20.April 8, 2025 | The Oxford Club (Ad)Akebia Therapeutics gets EU positive recommendation for XoanacylApril 3, 2025 | msn.comAkebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to AveroaApril 3, 2025 | globenewswire.comJefferies Financial Group Begins Coverage on Akebia Therapeutics (NASDAQ:AKBA)April 3, 2025 | americanbankingnews.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comAkebia initiated with a Buy at JefferiesApril 2, 2025 | markets.businessinsider.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.90 on January 1st, 2025. Since then, AKBA shares have decreased by 6.8% and is now trading at $1.77. View the best growth stocks for 2025 here. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its earnings results on Thursday, March, 13th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The biopharmaceutical company earned $46.50 million during the quarter, compared to the consensus estimate of $37.36 million. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM). Company Calendar Last Earnings3/13/2025Today4/08/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$7.50 Low Stock Price Target$6.00 Potential Upside/Downside+267.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,920,000.00 Net Margins-27.07% Pretax Margin-27.08% Return on EquityN/A Return on Assets-20.57% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.21 Sales & Book Value Annual Sales$160.18 million Price / Sales2.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-11.06Miscellaneous Outstanding Shares236,231,000Free Float209,236,000Market Cap$418.13 million OptionableOptionable Beta0.87 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AKBA) was last updated on 4/8/2025 by MarketBeat.com Staff From Our Partners10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThese obscure companies are Trump’s favorites?Ten investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | SponsoredDividend cuts are destroying retirements… is yours next?The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.